Compass Therapeutics, Inc.
US ˙ NasdaqCM ˙ US20454B1044

SecurityCMPX / Compass Therapeutics, Inc.
InstitutionSquarepoint Ops LLC
Latest Disclosed Ownership50,202 shares
Latest Disclosed Value $ 265,569
Squarepoint Ops LLC reports 60.22% decrease in ownership of CMPX / Compass Therapeutics, Inc.

On May 15, 2026 - Squarepoint Ops LLC filed a 13F-HR form disclosing ownership of 50,202 shares of Compass Therapeutics, Inc. (US:CMPX) valued at $265,569 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 126,192 shares of Compass Therapeutics, Inc.. This represents a change in shares of -60.22% during the quarter. The current value of the position is $105,424 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F COMPASS THERAPEUTICS COM 20454B104 50,202 -75,990 -60.22 266 -60.86 0.0003
2026-02-13 2025-12-31 13F COMPASS THERAPEUTICS COM 20454B104 126,192 38,339 43.64 678 120.52 0.0007
2025-11-14 2025-09-30 13F COMPASS THERAPEUTICS COM 20454B104 87,853 67,080 322.92 307 468.52 0.0003
2025-08-27 2025-06-30 13F/A-1 COMPASS THERAPEUTICS COM 20454B104 20,773 20,773 54 0.0001
2025-08-14 2025-06-30 13F COMPASS THERAPEUTICS COM 20454B104 20,773 20,773 54 0.0001
2025-08-27 2025-03-31 13F/A-1 COMPASS THERAPEUTICS COM 20454B104 0 -24,072 -100.00 0 -100.00
2025-05-15 2025-03-31 13F COMPASS THERAPEUTICS COM 20454B104 0 -24,072 0
2025-02-14 2024-12-31 13F COMPASS THERAPEUTICS COM 20454B104 24,072 24,072 35 0.0000
2024-11-14 2024-09-30 13F COMPASS THERAPEUTICS COM 20454B104 0 -64,133 -100.00 0 -100.00
2024-08-14 2024-06-30 13F COMPASS THERAPEUTICS COM 20454B104 64,133 13,321 26.22 64 -36.00 0.0001
2024-05-15 2024-03-31 13F COMPASS THERAPEUTICS COM 20454B104 50,812 -37,908 -42.73 101 -27.54 0.0002
2024-02-14 2023-12-31 13F COMPASS THERAPEUTICS COM 20454B104 88,720 88,720 138 0.0003
2023-08-14 2023-06-30 13F COMPASS THERAPEUTICS COM 20454B104 0 -16,263 -100.00 0 -100.00
2023-05-15 2023-03-31 13F COMPASS THERAPEUTICS COM 20454B104 16,263 16,263 53 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.